Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
3(27%)
Results Posted
0%(0 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
4
36%
Ph phase_2
2
18%
Ph phase_4
3
27%
Ph phase_3
2
18%

Phase Distribution

4

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

3

trials recruiting

Total Trials

11

all time

Status Distribution
Active(3)
Completed(4)
Terminated(3)
Other(1)

Detailed Status

Completed4
Recruiting3
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
3
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (36.4%)
Phase 22 (18.2%)
Phase 32 (18.2%)
Phase 43 (27.3%)

Trials by Status

completed436%
unknown19%
recruiting327%
terminated218%
withdrawn19%

Recent Activity

3 active trials
Showing 5 of 11
recruitingphase_2

Rupatadine in Patients With Ulcerative Colitis

NCT07064707
recruitingphase_1

Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants

NCT06708520
completedphase_1

Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants.

NCT06736340
withdrawnphase_4

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

NCT04601324
completedphase_1

A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions

NCT05356143
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07064707Phase 2

Rupatadine in Patients With Ulcerative Colitis

Recruiting
NCT06708520Phase 1

Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants

Recruiting
NCT06736340Phase 1

Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants.

Completed
NCT04601324Phase 4

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

Withdrawn
NCT05356143Phase 1

A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions

Completed
NCT03770923Phase 3

Effect of Some Drugs on Rheumatoid Arithritis Activity

Recruiting
NCT01605487Phase 2

Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria

Completed
NCT00162786Phase 4

Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance

Terminated
NCT00199251Phase 3

Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria

Terminated
NCT00199225Phase 1

Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers

Completed
NCT00258141Phase 4

Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11